<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472185</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-259-0131</org_study_id>
    <nct_id>NCT01472185</nct_id>
  </id_info>
  <brief_title>Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to
      determine the effect of ranolazine when given as monotherapy on glycemic control in subjects
      with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise
      alone and who are treatment naive to antihyperglycemic therapy or have not received
      antihyperglycemic therapy in the 90 days (or thiazolidinediones [TZDs] for at least 24 weeks)
      prior to screening, and to characterize the relationship between HbA1c reduction and other
      glycemic parameters in subjects with T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The average (mean) change from baseline in HbA1c at Week 24 was analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Serum Glucose at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HbA1c &lt; 7% at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.
Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at time [T] = 120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations and analyzed based on the randomized treatment regardless of actual treatment received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">465</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine tablets administered orally twice daily.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match ranolazine administered orally twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ranolazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>Participants are instructed to continue the diet regimen prescribed by their physician.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ranolazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Participants are instructed to continue the exercise regimen prescribed by their physician.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ranolazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Males and females, 18 to 75 years old, inclusive

          -  Documented history of T2DM

          -  Treatment naïve to antihyperglycemic therapy or having received no prior treatment
             with antihyperglycemic therapy for at least 90 days (TZDs for at least 24 weeks) prior
             to screening

          -  Body mass index (BMI) 25 kg/m2 to 45 kg/m2 inclusive at screening

          -  HbA1c 7% - 10%, inclusive at screening and at the end of the Qualifying Period (Day 14
             +2 days)

          -  Fasting serum glucose (FSG) of ≥ 130 mg/dL (7.2 mmol/L) and ≤ 240 mg/dL (13.3 mmol/L)
             at screening and at the end of the Qualifying Period (Day 14 +2 days). A one-time
             central laboratory re-test of FSG is allowed in subjects with an initial central
             laboratory FSG ≥ 125 mg/dL (6.9 mmol/L) and &lt; 130 mg/dL (7.2 mmol/L) who are otherwise
             eligible as determined by the investigator.

          -  Fasting serum C-peptide ≥ 0.8 ng/mL at screening

          -  Able and willing to comply with all study procedures during the course of the study

          -  Females of child-bearing potential must have a negative pregnancy test at screening
             and must agree to use highly effective contraception methods from screening throughout
             the duration of the Treatment Period and for 14 days following the last dose of study
             drug

          -  At least 80% compliant with dosing during the Qualifying Period

        Exclusion Criteria:

          -  History of or current diagnosis of type 1 diabetes mellitus

          -  History of diabetic ketoacidosis, ketosis-prone diabetes, or hyperosmolar
             hyperglycemic coma

          -  History of a severe episode of hypoglycemia (≥ 1 episode within 3 months prior to
             screening or ≥ 2 episodes within 6 months prior to screening), defined as hypoglycemia
             requiring 3rd party assistance to actively administer carbohydrate, glucagon, or other
             resuscitative actions due to severe impairment in consciousness or behavior

          -  Clinically significant complications of diabetes that, in the judgment of the
             investigator, would make the subject unsuitable to participate in this study

          -  History of any clinically significant cardiovascular or cerebrovascular event (eg,
             myocardial infarction [MI], acute coronary syndrome [ACS], recent coronary
             revascularization [including coronary artery bypass graft procedures or percutaneous
             coronary intervention], transient ischemic attack or ischemic stroke) ≤ 3 months prior
             to screening

          -  Inadequately controlled or unstable hypertension as defined by systolic blood pressure
             (SBP) &gt; 160 mmHg or diastolic blood pressure (DBP) &gt; 100 mmHg at screening and
             randomization

          -  Prolonged QTc interval &gt; 500 msec by ECG at screening, a personal or family history of
             QTc prolongation, congenital long QT syndrome, or subjects who are receiving drugs
             that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents,
             erythromycin, and certain antipsychotics (eg, ziprasidone)

          -  History of bariatric surgery at any time in the past or any other surgery &lt; 2 months
             before screening, or planning to undergo surgery during the study. Subjects with a
             planned minor surgery may be enrolled upon approval by the Medical Monitor.

          -  Any other hospitalization in the 14 days prior to screening or planned hospitalization
             at any time during the study

          -  Significant weight change (± 5%) &lt; 2 months prior to screening or on a weight-loss
             program and is not in the maintenance phase at screening

          -  Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) by
             the Modification of Diet in Renal Disease (MDRD) equation &lt; 30 mL/min/1.73 m2 at
             screening or undergoing any type of dialysis at screening or planning to undergo any
             type of dialysis during the course of the study.

          -  History of liver cirrhosis (Child-Pugh Class A, B or C)

          -  Active liver disease and/or significant abnormal liver function defined as aspartate
             aminotransferase (AST) &gt; 3x upper limit of the normal range (ULN) and/or alanine
             aminotransferase (ALT) &gt; 3x ULN and/or serum total bilirubin &gt; 2.0 mg/dL

          -  History of cancer (except non-melanomic skin cancers or cervical in situ) within 5
             years prior to screening

          -  History of alcohol or other drug abuse &lt; 12 months prior to screening

          -  Any other clinically significant existing medical or psychiatric condition, including
             clinically significant laboratory abnormalities, or one requiring further evaluation
             that, in the opinion of the investigator, could interfere with conduct of the study or
             interpretation of the data

          -  Prior treatment with open-label ranolazine or known hypersensitivity or intolerance to
             ranolazine or any of its excipients

          -  Treatment with strong or moderate cytochrome (CYP)3A inhibitors or P-glycoprotein
             (P-gp) inhibitors within 14 days prior to randomization

          -  Treatment with CYP3A inducers or P-gp inducers within 14 days prior to randomization

          -  Treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine,
             tacrolimus, sirolimus) within 14 days prior to randomization

          -  Treatment with simvastatin at a daily dose &gt; 20 mg or lovastatin at a daily dose &gt; 40
             mg, within 14 days prior to randomization

          -  Weight-loss medication or anti-obesity medication (prescription or nonprescription) &lt;
             3 months prior to screening

          -  Treatment with niacin &gt; 200 mg daily; if receiving ≤ 200 mg daily, should be on stable
             doses for ≥ 90 days prior to screening and for the duration of the study

          -  Expected or current treatment with systemic corticosteroids (oral or injectable) for &gt;
             14 days from screening through the end of the Treatment Period. Topical or inhaled
             corticosteroid formulations are permitted at any time during the study

          -  If receiving thyroid replacement therapy, should be on stable doses for at least 6
             weeks prior to randomization

          -  Hemoglobin &lt; 12 g/dL for males; or &lt; 11 g/dL for females, at screening

          -  Participation in another clinical study involving an investigational drug or device &lt;
             30 days prior to screening; participation in another clinical study involving an
             antihyperglycemic therapy &lt; 90 days prior to screening

          -  Donation of blood &lt; 2 months prior to screening; plans to donate blood while
             participating in the study

          -  Females who are pregnant or breastfeeding

          -  Other condition(s) that, in the opinion of the investigator, would compromise the
             safety of the subject, would prevent compliance with the study protocol (including the
             ability to comply with Mixed Meal Tolerance Test [MMTT]), or would compromise the
             quality of the clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thunderbird Internal Medicine/Clinical Research Advantage</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Phoenix Medical Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Sun Clinical Research, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eclipse Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Arkansas Medical Associates</name>
      <address>
        <city>Mountain Home</city>
        <state>Arkansas</state>
        <zip>72653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul W. Davis, MD, Private Practice</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southland Clinical Research Center, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Research Management</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Clinical Research Institute, Inc</name>
      <address>
        <city>Moreno Valley</city>
        <state>California</state>
        <zip>92553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacramento Heart and Vascular Medical Associates</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearview Medical Research LLC</name>
      <address>
        <city>Santa Clarita</city>
        <state>California</state>
        <zip>91350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infosphere Clinical Research</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boca Raton Clinical Research Associates, Inc</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Network, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605-4253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A G A Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NextPhase Clinical Trials, Inc.</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Organization</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Diabetes Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Institute for Clinical Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regenerate Clinical Trials</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Therapeutic Partners</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTL Research</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar-Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaPorte County Institute for Clinical Research</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Medical Research</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRC Clinics, Inc</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Internal Medicine Specialists, P.C.</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Clinical and Translational Science Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Inquest Center, Ltd.</name>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <zip>45431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Research Group, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blair Medical Associates, Inc, Station Medical Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Associates, Inc.</name>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <zip>29687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCCA Clinical Research Solutions</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCCA Clinical Research Solution</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCCA Clinical Research Solutions</name>
      <address>
        <city>Smyrrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humble Cardiology Associates</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Internal Medicine &amp; Research</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice s poliklinikou Havirov</name>
      <address>
        <city>Havirov</city>
        <state>Moravskoslezsky kraj</state>
        <zip>736 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Research Center</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Hungary Ltd</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Hospital</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanizsai Dorottya Hospital</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borbanya Praxis Kft., Outpatient Clinic</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medifarma 98</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala County Hospital</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>08900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Regionalna Poradnia Diabetologiczna</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Badan Klinicznych</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi, Oddział Kliniczny Diabetologii</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne Szpital Sw. Rodziny</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Polimedica</name>
      <address>
        <city>Zgierz</city>
        <state>Lodzkie</state>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LANDA - Specjalistyczne Gabinety Lekarskie</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Badan Klinicznych Oswiecim</name>
      <address>
        <city>Oswięcim</city>
        <state>Malopolskie</state>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ PrimaMED</name>
      <address>
        <city>Kielce</city>
        <state>Swietokrzyskie</state>
        <zip>25-364</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Osteporozy i Chorob Kostno-Stawowych J.Badurski Sp.j.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leszek Romanowski Barbara Romanowska &quot;DIABET&quot; Centrum Medyczne s.c.</name>
      <address>
        <city>Chrzanów</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczna Przychodnia Medyczna Atopia</name>
      <address>
        <city>Krakow</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Cereo-Med Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>92-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyzny Ośrodek Lecznicz-Badawczy</name>
      <address>
        <city>Ostroda</city>
        <zip>14-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miedzyleski Szpital Specjalistyczny w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Clinic Judetean de Urgenta Oradea Stationarul 1</name>
      <address>
        <city>Oradea</city>
        <state>Jud Bihor</state>
        <zip>410169</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitadiab SRL - Cabinet Medical Dr. Barabas Alina SRL</name>
      <address>
        <city>Brasov</city>
        <state>Jud Brasov</state>
        <zip>500269</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultmed SRL</name>
      <address>
        <city>Iasi</city>
        <state>Jud. Iasi</state>
        <zip>700547</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI Diabet Nutritie Boli Metabolice Dr. Pop Lavinia</name>
      <address>
        <city>Baia Mare</city>
        <state>Jud. Maramures</state>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI Morosanu V. Magdalena</name>
      <address>
        <city>Galati</city>
        <state>Judetul Galati</state>
        <zip>800371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta &quot;Sf. Apostol Andrei&quot; Galati</name>
      <address>
        <city>Galati</city>
        <state>Judetul Galati</state>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabmed Dr. Popescu Alexandrina SRL</name>
      <address>
        <city>Ploiesti</city>
        <state>Judetul Prahova</state>
        <zip>100163</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tehnomed Trading Srl</name>
      <address>
        <city>Bucharest</city>
        <zip>020354</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Diabet, Nutritie si Boli Metabolice &quot;Dr. N. C. Paulescu&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>020042</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.D. Medica Srl</name>
      <address>
        <city>Bucuresti</city>
        <zip>020725</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centru Medical Dr. Negrisanu</name>
      <address>
        <city>Timisoara, jud. Timis</city>
        <zip>300456</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Central Military Clinical Hospital named after A.A.Vishnevskogo</name>
      <address>
        <city>Arkhangelskoe</city>
        <zip>143420</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GOU VPO &quot;Chita State Medical Academy&quot; of Minzdravsocrazvitie RF</name>
      <address>
        <city>Chita</city>
        <zip>672090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Clinic of New Medical Technology&quot; Company Limited</name>
      <address>
        <city>Dzerzhinskiy</city>
        <zip>140091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urals State Medical Academy</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Krasnoyarsk State Medical University n.a. Prof. V.F. Voyno-Yasenetsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Moscow &quot;Cardiologival Dispensary #2 of Management Department of South Administrative District&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117556</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Sanitary Unit of Minestry of Internal Affairs of Russia in Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>127299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital #63</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 13 of Avtozavodsky District of Nizhniy Novgorod</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Medical University</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Reafan&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Physiology of Siberian Department RAMS</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630117</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital # 38 named after N A Semashko</name>
      <address>
        <city>Pushkin</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University</name>
      <address>
        <city>Ryazan</city>
        <zip>390005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center &quot;Diabetes&quot;, LLC</name>
      <address>
        <city>Samara</city>
        <zip>443067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical Academy, Sanatorium-Preventorium</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg City Outpatient Clinic#37</name>
      <address>
        <city>St. Petersburg</city>
        <zip>+011 78123152068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinet, LLC</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical Unversity n.a. I.I.Mechnikov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy named after S.M. Kirov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg state budgetary healthcare institution &quot;City Polyclinic #109&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192283</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexanders City Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital #122 n.a. Sokolov of FMBA</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ANO &quot;Medical Centre &quot;XXI century&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth City Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krestovsky Island Medical Institute, LLC</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197042</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Centre of Heart, Blood and Endocrinology named after V.A. Almazov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy named after S.M. Kirov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Center &quot;SOGAZ&quot;, LLC</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198168</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg City Pokrovskaya Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyumen State Medical Academy</name>
      <address>
        <city>Tyumen</city>
        <zip>625023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Hospital #1</name>
      <address>
        <city>Voronezh</city>
        <zip>394082</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital named after N.A.Semashko</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital for Emergency Care named after N.V. Solovyov</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Sanitary Unit of Novo-Yaroslavsky Oil Refinery</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>METABOLKLINIK s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <state>Bratislavsky kraj</state>
        <zip>811 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Center of Dr. Katarina Raslova Ltd.</name>
      <address>
        <city>Bratislava</city>
        <state>Bratislavsky kraj</state>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Diabetologicka a metabolicka ambulancia Human-care s.r.o&quot;</name>
      <address>
        <city>Kosice</city>
        <state>Kosicky kraj</state>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARETEUS s.r.o., Diabetologicka ambulancia</name>
      <address>
        <city>Trebisov</city>
        <state>Kosicky kraj</state>
        <zip>07501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENDIAMED s.r.o</name>
      <address>
        <city>Dolny Kubin</city>
        <state>Zilinsky kraj</state>
        <zip>02601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDIVASA s.r.o.</name>
      <address>
        <city>Zilina</city>
        <state>Zilinsky kraj</state>
        <zip>010 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediVet s.r.o.</name>
      <address>
        <city>Malacky</city>
        <zip>901 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newkwa Medical Centre</name>
      <address>
        <city>Newlands West</city>
        <state>Durban</state>
        <zip>4037</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Umhlanga Medical Centre</name>
      <address>
        <city>Kwa Zulu Natal</city>
        <state>Umhlanga, Durban</state>
        <zip>4320</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthwhile Clinical Trials</name>
      <address>
        <city>Benoni</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Diabetes, Asthma and Allergy</name>
      <address>
        <city>Johannesburg</city>
        <zip>01829</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto Clinical Trial Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aliwal Shoal Medical &amp; Clinical Trial Centre</name>
      <address>
        <city>Kwa Zulu Natal</city>
        <zip>4170</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Clinical Trials</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helderberg Clinical Trials Centre</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiervlei Trial Centre</name>
      <address>
        <city>Western Cape</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital#9, Dnipropetrovsk State Medical Academy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Educational Scientific Medical Centre &quot;University clinic&quot; of Donetsk National Medical University n.a. M.Gorkiy</name>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Institute of Problems of Endocrine Pathology n.a. V.Y. Danylevsky of NAMS of Ukraine&quot;</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administration of Medical Service and Rehabilitation of &quot;ARTEM&quot; State Holding Company</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical University n.a. O.O. Bogomolets, Chair of Family Medicine based on Outpatient Clinic # 2 of Shevchenkovsky District</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V. P. Komissarenko Institute of Endocrinology and Metabolism of AMS of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Lutsk City Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Endocrinology Dispensary</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa State Medical University</name>
      <address>
        <city>Odesa</city>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Institution &quot;City Outpatients' Hospital #20&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsya Regional Clinical Endocrinology Dispensary</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhytomyr Regional Clinical Hospital</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <results_first_submitted>October 8, 2014</results_first_submitted>
  <results_first_submitted_qc>October 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2014</results_first_posted>
  <disposition_first_submitted>December 12, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 12, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 14, 2014</disposition_first_posted>
  <last_update_submitted>October 15, 2014</last_update_submitted>
  <last_update_submitted_qc>October 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at a total of 113 study sites in the United States, South Africa, Europe, and Russia. The first participant was screened on 15 November 2011. The last participant observation occurred on 21 October 2013.</recruitment_details>
      <pre_assignment_details>605 participants entered the qualifying period; 465 were randomized, and 464 were randomized and treated (Safety Analysis Set). Of these, 8 were excluded due to major eligibility criteria protocol violation or had baseline but no on-treatment data; thus, 456 were included in the Full Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
        </group>
        <group group_id="P2">
          <title>Ranolazine</title>
          <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event Other than Hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator’s Discretion</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are reported for the Safety Analysis Set following randomization. The Safety Analysis Set includes randomized participants who received at least one dose of study treatment, analyzed based on actual treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
        </group>
        <group group_id="B2">
          <title>Ranolazine</title>
          <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="232"/>
            <count group_id="B2" value="232"/>
            <count group_id="B3" value="464"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="9.3"/>
                    <measurement group_id="B2" value="55" spread="9.5"/>
                    <measurement group_id="B3" value="56" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Permitted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All randomized participants were analyzed for region of enrollment (placebo, n = 232; ranolazine, n = 233).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="4.85"/>
                    <measurement group_id="B2" value="32.8" spread="4.75"/>
                    <measurement group_id="B3" value="32.8" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated hemoglobin (HbA1c)</title>
          <units>percent HbA1c in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.01" spread="0.727"/>
                    <measurement group_id="B2" value="8.06" spread="0.732"/>
                    <measurement group_id="B3" value="8.04" spread="0.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Serum Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.5" spread="34.45"/>
                    <measurement group_id="B2" value="172.1" spread="34.32"/>
                    <measurement group_id="B3" value="171.8" spread="34.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" spread="4.00"/>
                    <measurement group_id="B2" value="3.0" spread="4.29"/>
                    <measurement group_id="B3" value="3.0" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate (eGFR)</title>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.3" spread="18.40"/>
                    <measurement group_id="B2" value="84.5" spread="18.80"/>
                    <measurement group_id="B3" value="83.9" spread="18.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</title>
        <description>The average (mean) change from baseline in HbA1c at Week 24 was analyzed.</description>
        <time_frame>Baseline; Week 24</time_frame>
        <population>Participants in the Full Analysis Set (randomized participants who received ≥ 1 dose of study treatment with a baseline and at least one postbaseline measurement of HbA1c, excluding subjects with major eligibility violations and analyzed based on the randomized treatment regardless of actual treatment received) with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</title>
          <description>The average (mean) change from baseline in HbA1c at Week 24 was analyzed.</description>
          <population>Participants in the Full Analysis Set (randomized participants who received ≥ 1 dose of study treatment with a baseline and at least one postbaseline measurement of HbA1c, excluding subjects with major eligibility violations and analyzed based on the randomized treatment regardless of actual treatment received) with available data were analyzed.</population>
          <units>percent of HbA1c in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.70" spread="1.183"/>
                    <measurement group_id="O2" value="7.26" spread="1.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in HbA1c at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="1.027"/>
                    <measurement group_id="O2" value="-0.80" spread="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a common standard deviation of 1.2%, an effective sample size of 400 would provide at least 90% power to detect a statistically significant treatment difference of -0.5% (ranolazine vs. placebo) for the reduction of HbA1c from baseline at Week 24 based on a 2-sided alpha of 0.05 and 1:1 randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>P-value is from a mixed effects model including terms for baseline HbA1c value, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.</p_value_desc>
            <method>Mixed Effects Model Analysis</method>
            <param_type>difference in least squares mean (LSM)</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
            <estimate_desc>The estimation (LSM) is of the placebo-corrected change from baseline.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Serum Glucose at Week 24</title>
        <description>The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.</description>
        <time_frame>Baseline; Week 24</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Serum Glucose at Week 24</title>
          <description>The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.</description>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="42.2"/>
                    <measurement group_id="O2" value="-7" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HbA1c &lt; 7% at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>Participants in the Full Analysis Set with Baseline HbA1c ≥ 7% and available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HbA1c &lt; 7% at Week 24</title>
          <population>Participants in the Full Analysis Set with Baseline HbA1c ≥ 7% and available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24</title>
        <description>The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.
Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at time [T] = 120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations and analyzed based on the randomized treatment regardless of actual treatment received.</description>
        <time_frame>Baseline; Week 24</time_frame>
        <population>Participants in the Mixed Meal Tolerance Test (MMTT) Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24</title>
          <description>The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.
Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at time [T] = 120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations and analyzed based on the randomized treatment regardless of actual treatment received.</description>
          <population>Participants in the Mixed Meal Tolerance Test (MMTT) Full Analysis Set with available data were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="65.1"/>
                    <measurement group_id="O2" value="-19" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24</title>
        <description>The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.</description>
        <time_frame>Baseline; Week 24</time_frame>
        <population>Participants in the Mixed Meal Tolerance Test (MMTT) Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine</title>
            <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24</title>
          <description>The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.</description>
          <population>Participants in the Mixed Meal Tolerance Test (MMTT) Full Analysis Set with available data were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="47.7"/>
                    <measurement group_id="O2" value="-12" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 Weeks plus 30 days</time_frame>
      <desc>Safety Analysis Set: randomized participants who received at least one dose of study treatment, analyzed based on actual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Placebo to match ranolazine (Days 1–7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
        </group>
        <group group_id="E2">
          <title>Ranolazine</title>
          <description>Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
Treatment Period: Ranolazine tablets (Days 1–7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
Participants were required to maintain their diet and exercise regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-small cell lung cancer stage iv</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences, Inc.</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

